| 12/05 | Roche believes cancer drug setback not a fatal blow to growth prospects |  |
| 10/05 | Biogen Says Eisai Submits Biologics License Application for Lecanemab for Alzheimer's D.. | |
| 10/05 | Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of.. | |
| 06/05 | Japanese shares rise on energy, financials boost | |
| 05/05 | Biogen Partners With MedRhythms to Develop, Commercialize Potential Treatment for Gait .. | |
| 05/05 | Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T.. | |
| 05/05 | Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T.. | |
| 05/05 | Biogen and MedRhythms to Develop and Commercialize a Prescription Digital Therapeutic T.. | |
| 05/05 | Biogen and MedRhythms to Develop and Commercialize A Prescription Digital Therapeutic T.. | |
| 05/05 | Xbrane Biopharma releases interim report for January – March 2022 | |
| 05/05 | Michel Vounatsos to Step Down as Chief Executive Officer of Biogen | |
| 04/05 | MARKETSCREENER'S WORLD PRESS REVIEW : May 4, 2022 | |
| 03/05 | BIOGEN INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF.. | |
| 03/05 | Tranche Update on Biogen Inc.'s Equity Buyback Plan announced on October 21, 2020. | |
| 03/05 | Change at the top for Biogen after Alzheimer's drug flops | |
| 03/05 | Biogen's Quarterly Results Fall as Drugmaker Plans to Stop Selling Aduhelm; CEO to Step.. | |
| 03/05 | TIMELINE-Biogen CEO to leave as Alzheimer's drug struggles | |
| 03/05 | GLOBAL MARKETS LIVE : BP, Pfizer, Expedia, Citigroup, Amazon... | |
| 03/05 | NACH PROBLEMEN MIT ALZHEIMER-MITTEL : Biogen will Chef austauschen |  |
| 03/05 | Nervousness is apparent ahead of Fed speech | |
| 03/05 | SECTOR UPDATE : Health Care Stocks Mixed Premarket Tuesday | |
| 03/05 | Biogen Q1 Non-GAAP EPS, Revenue Drop; CEO Michel Vounatsos to Leave; Reaffirms 2022 Gui.. | |
| 03/05 | Biogen gana 535 millones en el trimestre, un 34% menos que en 2021 |  |
| 03/05 | TRANSCRIPT : Biogen Inc., Q1 2022 Earnings Call, May 03, 2022 | |
| 03/05 | BIOGEN INC. : Results of Operations and Financial Condition, Change in Directors or Princi.. | |
| 03/05 | Biogen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 | |
| 03/05 | Biogen Inc. Reaffirms Revenue Guidance for the Full Year 2022 | |
| 03/05 | Biogen CEO to step down; drugmaker pulls back on Alzheimer's drug Aduhelm | |
| 03/05 | Biogen quarterly profit falls 26% | |
| 02/05 | Biogen, Scribe Therapeutics Expand Research Collaboration to Second Disease Target | |
| 02/05 | Sage, Biogen Start Rolling Submission of New-Drug Application to US FDA for Major Depre.. | |
| 02/05 | L'agenda di domani |  |
| 02/05 | Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application to U.S.. | |
| 02/05 | L'agenda della settimana | |
| 30/04 | BIOGEN : Statement Regarding Updated ADUHELM® (aducanumab-avwa) Prescribing Information in.. | |
| 29/04 | L'agenda della prossima settimana | |
| 28/04 | Eli Lilly obesity drug data shines, shares rise | |
| 28/04 | Samsung Biologics Completes Full Acquisition Of Samsung Bioepis | |
| 27/04 | Big Biotech Firms Have Several Catalysts Lined Up, UBS Says | |
| 22/04 | Biogen Withdraws European Marketing Authorization Application for Alzheimer's Disease D.. | |
| 22/04 | Biogen pulls application for Alzheimer's drug in Europe | |
| 22/04 | Biogen to withdraw Alzheimer's drug application in Europe | |
| 22/04 | BIOGEN : Update on Regulatory Submission for Aducanumab in the European Union | |
| 22/04 | Biogen Pulls European Application for Approval of Alzheimer's Drug Aduhelm | |
| 20/04 | BIOGEN : Completes Sale of Equity Stake in Biosimilar Joint Venture to Samsung Biologics f.. | |
| 20/04 | Samsung Biologics Co.,Ltd. completed the acquisition of the remaining 49.9% stake in Sa.. | |
| 11/04 | Moody's Downgrades Biogen to Baa2 From Baa1; Outlook Negative | |
| 09/04 | Alzheimer's drugmakers seek accelerated FDA review despite U.S. coverage decision | |
| 08/04 | TIMELINE-Alzheimer's drug from Biogen hits Medicare coverage curbs | |
| 08/04 | MARKETSCREENER'S WORLD PRESS REVIEW : April 8, 2022 | |
| 08/04 | SECTOR UPDATE : Health Care Stocks Edge Upward Premarket Friday | |
| 08/04 | SECTOR UPDATE : Health Care | |
| 08/04 | Vir Biotechnology Appoints Johanna Friedl-Naderer as COO | |
| 08/04 | BIOGEN : Statement on the Final National Coverage Determination for Amyloid-Beta Targeting.. | |
| 07/04 | U.S. Medicare limits coverage for Biogen's Alzheimer's drug | |
| 07/04 | Medicare Limits Coverage Policy for Biogen's Alzheimer's Drug -- Shares Slide After-Hou.. | |
| 07/04 | Medicare Officially Limits Coverage Of Aduhelm To Patients In Clinical Trials- NYT | |
| 05/04 | BIOGEN : to Report First Quarter 2022 Financial Results May 3, 2022 | |
| 04/04 | New Data at AAN 2022 Highlight Real-World Evidence from Biogen's MS Portfolio and Emerg.. | |
| 04/04 | Biogen Inc. Announces New Data from Portfolio of Multiple Sclerosis Therapies | |
| 04/04 | SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bioge.. | |
| 30/03 | Biogen Submits Final Study Protocol for Alzheimer's Injection to FDA | |
| 30/03 | Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to .. | |
| 30/03 | Biogen Submits Final Protocol for ADUHELM (aducanumab-avwa) Phase 4 Envision Trial to F.. | |
| 28/03 | LATE BRIEFING - Unternehmen und Märkte -2- | |
| 28/03 | TRANSCRIPT : Biogen Inc. Presents at Stifel CNS Days, Mar-28-2022 10:15 AM | |
| 28/03 | SECTOR UPDATE : Health Care Stocks Edge Higher Pre-Bell Monday | |
| 28/03 | Wall Street Wavers Pre-Bell as Data-Heavy Week Kicks Off | |
| 28/03 | Top Premarket Decliners | |
| 28/03 | Biogen, Ionis Pharmaceuticals Discontinue Clinical Program for Amyotrophic Lateral Scle.. | |
| 28/03 | Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9or.. | |
| 28/03 | Biogen Inc. and Ionis Pharmaceuticals, Inc. Announce Topline Phase 1 Study Results of B.. | |
| 28/03 | Biogen, Ionis End Development of ALS Candidate After Study Failure | |
| 23/03 | Eisai Co., Ltd - LATEST FINDINGS ON LECANEMAB - CLINICAL EFFICACY, ARIA RATES, BIOMARKE.. | |
| 23/03 | InnoCare Pharma Narrows Loss on License-Out Payment From Biogen for Multiple Sclerosis .. | |
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Italiano
Nederlands (Nederland)
Nederlands (België)
bourse
Rapport
